Wells Fargo & Company Cns Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.19 - $292.65 $2 - $4,097	14 Added 0.11%	12,210 $2,000
Q2 2022 Aug 12, 2022	BUY	$0.26 - $0.43 $8 - $14	33 Added 0.27%	12,196 $3,000
Q1 2022 May 16, 2022	BUY	$0.26 - $1.05 $15 - $63	60 Added 0.5%	12,163 $4,000
Q4 2021 Feb 14, 2022	SELL	$0.7 - $1.54 $1,219 - $2,682	-1,742 Reduced 12.58%	12,103 $8,000
Q3 2021 Nov 15, 2021	SELL	$1.4 - $1.98 $7 - $9	-5 Reduced 0.04%	13,845 $20,000
Q1 2021 May 13, 2021	BUY	$1.72 - $4.18 $23,751 - $57,721	13,809 Added 33680.49%	13,850 $33,000
Q3 2020 Nov 05, 2020	BUY	$1.69 - $2.64 $43 - $68	26 Added 173.33%	41 $0
Q1 2020 May 14, 2020	BUY	$1.45 - $4.99 $21 - $74	15 New	15 $0

100

Ticker CNSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,032,500
Market Cap $4.4M
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme....

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.